Latest Breaking News On - Professor loreto gesualdo - Page 1 : comparemela.com

World Sepsis Day September 13, 2023: ABIONYX Pharma Confirms Its Commitment to Sepsis, a Global Public Health Issue

World Sepsis Day September 13, 2023: ABIONYX Pharma Confirms Its Commitment to Sepsis, a Global Public Health Issue
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Baden wübergLoreto gesualdoNicolas fossiezAntonio crovaceArthur rouillPierre piorrySalvatore grassoLouis victor delouvrierUniversity of bariDepartment of nephrologyWorld sepsisScientific reportsAntimicrobial resistanceProfessor loreto gesualdoTemporary authorizationNamed use

CER-001 identified as potential treatment for septic patients

A Phase II pilot study demonstrated CER-001 is a potentially game-changing treatment for septic patients at high risk of acute kidney injury.

Loreto gesualdoConnie peyrottesUniversity of bari aldo moroProfessor loreto gesualdoTransplantation unitBari aldo moroKidney diseaseImproving global outcomesHigh density lipoprotein

ABIONYX Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury

ABIONYX Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury
businesswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswire.com Daily Mail and Mail on Sunday newspapers.

Loreto gesualdoValutazioni biologichee farmacologicheConnie peyrottesSalvatore grassoUniversity of bari aldo moroConsortium forUniversity of bariRegulatory newsTemporary authorizationNamed useAcute kidney injuryTransplantation unitResuscitation unitSequential organ failure assessmentValutazioni biologicheProfessor loreto gesualdo

ABIONYX Pharma: ABIONYX Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury

ABIONYX Pharma: ABIONYX Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury Temporary Authorization for Named Use (ATUn) showed promising efficacy in renal diseases Evaluation of the clinical activity by dosage level of CER-001 in the prevention of Acute Kidney Injury in ICU patients with septicemia A potentially modifying effect on the progression of the inflammatory cascade in sepsis Pending positive data, the company aims to move into Phase 2b by end of 2021 Regulatory News: ABIONYX Pharma ( FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces that it has received authorization from the Italian authorities to launch a clinical trial named

Loreto gesualdoValutazioni biologichee farmacologicheLouis victor delouvrierNicolas merigeauConnie peyrottesSalvatore grassoUniversity of bari aldo moroConsortium forUniversity of bariNamed useAcute kidney injuryTemporary authorizationTransplantation unitResuscitation unitSequential organ failure assessmentValutazioni biologiche